recombin
nucleocapsid
protein
rnp
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
express
baculoviru
system
purifi
sarscov
rnp
use
antigen
detect
sarscov
antibodi
igg
enzymelink
immunosorb
assay
elisa
elisa
evalu
comparison
neutral
antibodi
assay
authent
sarscov
antigenbas
igg
elisa
twohundr
seventysix
serum
sampl
collect
health
care
worker
hospit
nosocomi
sar
outbreak
took
place
use
evalu
sarscov
rnpbase
igg
elisa
sensit
specif
compar
neutral
antibodi
assay
sensit
specif
compar
authent
sarscov
antigenbas
igg
elisa
result
suggest
newli
develop
sarscov
rnpbase
igg
elisa
valuabl
tool
diagnosi
seroepidemiolog
studi
sar
sarscov
rnpbase
igg
elisa
advantag
convent
igg
elisa
antigen
prepar
laboratori
worker
without
risk
infect
sever
acut
respiratori
syndrom
sar
emerg
viru
infect
respiratori
organ
high
mortal
rate
human
first
report
guangdong
provinc
southern
part
china
novemb
spread
hong
kong
vietnam
singapor
countri
worldwid
humantohuman
transmiss
cdc
lee
et
al
poutanen
et
al
tsang
et
al
approxim
patient
report
die
last
sar
outbreak
novemb
juli
caus
agent
sar
coronaviru
sarscov
isol
patient
sar
identifi
novel
coronaviru
sarscov
transmit
human
human
mortal
rate
high
sarscov
regard
viral
pathogen
must
handl
high
contain
laboratori
biosafeti
level
bsl
recombin
protein
sarscov
use
antigen
serolog
diagnosi
sarscov
infect
offer
advantag
prepar
sarscov
antigen
recombin
protein
sarscov
produc
without
risk
sarscovinfect
among
laboratori
worker
present
studi
develop
igg
enzymelink
immunosorb
assay
elisa
recombin
nucleocapsid
protein
rnp
sarscov
sarscov
rnp
use
antigen
evalu
efficaci
elisa
use
serum
sampl
collect
health
care
worker
hospit
hit
sarsnosocomi
outbreak
sarscov
use
studi
kindli
suppli
prof
js
malik
peiri
depart
microbiolog
univers
hong
kong
hong
kong
special
administr
region
vero
cell
purchas
american
type
cell
collect
manassa
va
grown
eagl
minimum
essenti
medium
mem
supplement
penicillin
g
streptomycin
fetal
bovin
serum
fb
confirm
inhibitori
effect
growth
sarscov
cell
cultur
preliminari
studi
sarscov
grown
vero
cell
cultur
mem
penicillin
g
streptomycin
fetal
bovin
serum
two
hundr
seventysix
serum
sampl
collect
health
care
worker
hanoi
french
hospit
ho
chi
min
citi
vietnam
use
vu
et
al
serial
serum
sampl
collect
subject
differ
occas
sera
use
serolog
analys
heatinactiv
treatment
c
min
procedur
requir
manipul
infecti
sarscov
andor
noninactiv
clinic
sampl
neutral
antibodi
assay
authent
sarscov
antigen
prepar
conduct
laboratori
nation
institut
infecti
diseas
tokyo
japan
rna
extract
sarscov
infect
vero
cell
revers
transcrib
use
random
hexam
n
gene
sarscov
amplifi
random
hexamerprim
strand
dna
use
forward
primer
nbamf
gga
tcc
aat
taa
aat
gtc
tga
taa
tgg
acc
bamhi
restrict
site
underlin
revers
primer
gga
tcc
tgc
ctg
agt
tga
atc
agc
bamhi
restrict
site
underlin
pcr
product
purifi
agarosegel
electrophoresi
clone
pgemteasi
vector
promega
madison
usa
gener
pgemteasyn
sequenc
confirm
ident
origin
sequenc
genbank
access
n
gene
insert
excis
bamhi
pgemteasyn
ligat
uniqu
bamhi
site
modifi
baculovirustransf
plasmid
pacchi
carri
extrem
uniqu
bamhi
site
recombin
baculoviru
acsarsnhi
gener
use
method
describ
kitt
et
al
vero
cell
infect
sarscov
specif
antigen
product
also
mockinfect
control
antigen
extract
made
similarli
follow
authent
sarscov
antigen
correspond
mockantigen
produc
follow
vero
cell
infect
sarscov
mock
viru
multipl
infect
moi
respect
incub
h
authent
sarscovand
mockinfect
vero
cell
collect
cell
wash
twice
cold
phosphatebuff
salin
pb
solut
suspend
phosphatebuff
salin
solut
supplement
cellsuspend
solut
incub
ice
min
cell
lysat
centrifug
rpm
min
c
supernat
fraction
prepar
sarscovand
mockinfect
vero
cell
inactiv
ultraviolet
irradi
use
posit
neg
antigen
igg
elisa
respect
insect
cell
infect
acsar
nhi
acp
baculoviru
express
polyhedrin
incub
h
c
respect
group
cell
wash
twice
cold
pb
lyse
cold
pb
contain
urea
cell
lysat
centrifug
rpm
c
min
supernat
fraction
collect
sourc
sarscov
rnp
neg
control
antigen
purif
sarscov
rnp
neg
control
antigen
purifi
use
ni
resin
purif
system
qiagen
gmbh
hilden
germani
accord
manufactur
instruct
authent
sarscov
agbas
sarscov
rnpbase
igg
elisa
perform
describ
previous
except
antigen
prepar
saijo
et
al
saijo
et
al
antigen
dilut
mm
carbon
buffer
ph
use
coat
well
elisa
plate
present
studi
serum
sampl
heatinactiv
dilut
twofold
test
sampl
l
volum
mix
volum
mem
contain
sarscov
infecti
dose
plaqu
form
unit
per
l
mixtur
incub
h
c
neutral
incub
mixtur
test
neutral
cytopath
effect
cpe
inhibit
assay
use
vero
cell
neutral
antibodi
titer
defin
reciproc
highest
dilut
cpe
observ
sarscov
rna
genom
amplifi
use
loopamp
sar
covdetect
kit
eiken
chemic
ohtawara
japan
report
previous
modif
rna
isol
serum
sampl
use
qiaamp
viral
rna
mini
kit
qiagen
germani
primer
use
loopamp
sar
covdetect
kit
sarscov
rna
amplif
design
accord
nucleotid
sequenc
replicas
region
genbank
access
number
nc
revers
transcriptionlamp
reaction
conduct
l
reaction
mixtur
c
min
use
realtim
turbidimet
teramec
japan
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
sarscov
rnpbase
igg
elisa
calcul
comparison
neutral
antibodi
assay
naiv
sarscov
antigenbas
igg
elisa
qing
et
al
receiv
oper
characterist
roc
twographroc
tgroc
curv
analyz
use
stat
flex
version
softwar
artech
co
ltd
osaka
japan
greiner
et
al
qing
et
al
relationship
od
sarscov
rnpbase
igg
elisa
authent
viral
antigenbas
igg
elisa
neutral
antibodi
titer
evalu
spearman
correl
coeffici
rank
use
statview
softwar
version
sa
institut
inc
cari
nc
sarscov
rnp
effici
express
insect
cell
infect
recombin
acsarsnhi
purifi
sarscov
rnp
visual
detect
sdspage
analysi
data
shown
serum
sampl
show
posit
reaction
neutral
antibodi
assay
relationship
neutral
antibodi
titer
od
valu
sarscov
rnpbase
igg
elisa
dilut
level
evalu
use
neutral
antibodyposit
sampl
signific
posit
correl
neutral
antibodi
titer
od
valu
sarscov
rnpbase
igg
elisa
fig
r
p
sensit
specif
ppv
npv
roc
area
sarscov
rnpbase
igg
elisa
calcul
use
sampl
determin
either
posit
neg
neutral
antibodi
assay
authent
sarscovbas
igg
elisa
rel
sensit
specif
curv
sarscov
rnpbase
igg
elisa
use
tgroc
analysi
shown
fig
sensit
specif
ppv
npv
sarscov
rnpbase
igg
elisa
respect
cutoff
valu
set
od
valu
intersect
point
fig
roc
area
sarscov
rnpbase
igg
elisa
compar
either
neutral
antibodi
assay
respect
valu
sarscov
rnpbase
igg
elisa
respect
compar
naiv
sarscov
antigenbas
igg
elisa
cutoff
valu
set
od
valu
determin
way
mention
seroconvers
neutral
antibodi
assay
demonstr
subject
serial
serum
sampl
collect
differ
occas
sequenti
chang
od
sarscov
rnpbase
igg
sarscov
rnpbase
igg
elisa
dilut
neutral
antibodi
titer
two
serum
sampl
collect
subject
differ
occas
black
red
blue
arrow
indic
subject
neg
neutral
antibodi
neg
antibodi
detect
sarscov
rnpbase
igg
elisa
stage
first
blood
collect
neg
neutral
antibodi
posit
antibodi
detect
elisa
stage
subject
posit
neutral
antibodi
neg
antibodi
detect
elisa
stage
respect
green
arrow
indic
subject
posit
neutral
antibodi
posit
antibodi
detect
elisa
stage
elisa
dilut
neutral
antibodi
titer
among
serum
sampl
collect
seroconversionposit
subject
evalu
fig
serum
sampl
collect
first
sub
ject
show
neg
neutral
antibodi
titer
less
black
blue
red
line
fig
serum
sampl
collect
two
subject
show
posit
neutral
antibodi
titer
green
line
fig
four
neutral
antibodyneg
sampl
show
posit
reaction
sarscov
rnpbase
igg
elisa
red
line
fig
show
neg
reaction
neutral
antibodi
assay
black
blue
line
one
sampl
show
posit
reaction
titer
neutral
antibodi
assay
show
neg
reaction
sarscov
rnpbase
igg
elisa
blue
line
fig
sarscov
rna
amplifi
lamp
method
serum
sampl
collect
nine
subject
statu
antibodi
sarscov
serum
sampl
evalu
seven
sampl
show
neg
reaction
method
neutral
antibodi
assay
sarscov
rnpbase
igg
elisa
two
show
neg
reaction
neutral
antibodi
assay
posit
reaction
elisa
sampl
show
posit
reaction
assay
fig
sarscov
reveal
kb
long
viral
genom
contain
potenti
open
read
frame
orf
sequenc
sarscov
reveal
presenc
orf
four
structur
protein
ie
spike
membran
envelop
nucleocapsid
protein
among
structur
protein
select
nucleocapsid
protein
sarscov
rnp
antigen
tan
et
al
recent
report
antibodi
nucleocapsid
spike
protein
sarscov
demonstr
convalescentphas
patient
antibodi
protein
uniqu
sasrcov
demonstr
patient
indic
sarscov
rnp
best
choic
antigen
among
sarscov
structur
protein
similar
result
report
woo
et
al
studi
perform
use
rel
larg
panel
serum
sampl
collect
health
care
worker
vietnames
hospit
develop
recombin
sarscov
nucleocapsid
proteinbas
igg
elisa
confirm
elisa
higher
sensit
specif
detect
igg
antibodi
sarscov
compar
neutral
antibodi
assay
gold
standard
method
authent
sarscov
agbas
igg
elisa
fig
posit
correl
od
valu
sarscov
rnpbase
igg
elisa
neutral
antibodi
titer
fig
furthermor
sequenti
chang
od
sarscov
rnpbase
igg
elisa
neutral
antibodi
titer
subject
seroconvers
demonstr
evalu
fig
four
alreadi
antibodi
sarscov
rnp
detect
sarscov
rnpbase
igg
elisa
although
stage
yet
neutral
antibodi
equal
hand
one
serum
sampl
show
posit
reaction
neutral
antibodi
assay
titer
show
neg
reaction
sarscov
rnpbase
igg
elisa
fig
result
suggest
sarscov
rnpbase
igg
elisa
sensit
neutral
antibodi
assay
therefor
conclud
newli
develop
sarscov
rnpbase
igg
elisa
use
serolog
diagnosi
seroepidemiolog
studi
sarscov
infect
sarscov
rnpbase
igg
elisa
evalu
efficaci
detect
specif
antibodi
sarscov
comparison
neutral
antibodi
assay
present
studi
sever
report
sarscov
rnpbase
serolog
diagnost
system
chan
et
al
guan
et
al
lin
et
al
shi
et
al
woo
et
al
lin
et
al
first
report
sarscov
rnp
would
one
candid
antigen
detect
sarscov
antibodi
confirm
three
nine
serum
sampl
collect
patient
clinic
diagnos
sar
show
posit
reaction
sarscov
rnpbase
western
blot
sarscov
rnp
express
e
coli
system
use
antigen
antigencaptur
elisa
report
antigencaptur
elisa
high
specif
though
sensit
evalu
studi
recent
guan
et
al
also
report
efficaci
recombin
protein
sarscovbas
igg
elisa
diagnosi
sar
sarscov
rnp
also
express
e
coli
transform
express
vector
howev
system
compar
neutral
antibodi
assay
consid
gold
standard
indic
sensit
specif
ppv
npv
elisa
rel
lower
previou
report
shi
et
al
differ
might
due
differ
natur
sera
use
studi
due
method
evalu
due
factor
statu
antibodi
sarscov
sarscov
genomeposit
serum
sampl
evalu
reveal
sarscov
genom
still
present
stage
igg
respons
case
sar
fig
result
indic
handl
blood
collect
patient
sar
must
handl
care
even
patient
recoveri
phase
igg
respons
furthermor
sarscov
amplif
sensit
assay
lamp
method
carri
diagnost
tool
even
patient
sar
stage
igg
respons
summari
sarscov
rnpbase
igg
elisa
high
sensit
specif
develop
advantag
sarscov
rnpbase
igg
elisa
antigen
prepar
without
risk
infect
